GNG4, as a potential predictor of prognosis, is correlated with immune infiltrates in colon adenocarcinoma

Abstract

The tumour microenvironment (TME) and immunosuppression play an important role in colon cancer (CC) metastasis, which seriously affects the prognosis of CC. G protein subunit gamma 4 (GNG4) has been shown to participate in tumour progression and the tumour mutation burden (TMB) in colorectal cancer. However, the effect of GNG4 on the CC TME and immunology remains elusive. Weighted gene coexpression network analysis (WGCNA) was employed for screening aberrantly expressed genes associated with the immune score, and GNG4 was then selected through prognostic and immune correlation analysis. Based on RNA sequencing data obtained from the TCGA and GEO databases, the expression pattern and immune characteristics of GNG4 were comprehensively examined using a pan‐cancer analysis. Upregulation of GNG4 was linked to an adverse prognosis and immune inhibitory phenotype in CC. Pan‐cancer analysis demonstrated higher GNG4 expression in tumours than in paired normal tissue in human cancers. GNG4 expression was closely related to prognosis, TMB, immune checkpoints (ICPs), microsatellite instability (MSI) and neoantigens. GNG4 promoted CC cell proliferation, migration and invasion and participated in immune regulation in the TME. Significantly, GNG4 expression was found to negatively correlate with tumour‐infiltrating immune cells, ICP, TMB and MSI in CC. GNG4 expression predicted the immunotherapy response in the IMvigor210 cohort, suggesting that GNG4 could be used as a potential biomarker in CC for prognostication and immunology. Moreover, the expression of GNG4 predicted the immunotherapy response of ICB in CC.

Development and verification of a novel immunogenic cell death‐related signature for predicting the prognosis and immune infiltration in triple‐negative breast cancer

“…We therefore selected the IMvigor210 cohort including 348 urothelial carcinoma patients who received immunotherapy, which is the most widely used cohort of similar studies. [57][58][59] In the future, more research on TNBC immunotherapy responses and updates of related public databases will help to improve this issue. In addition, low ICD score group also had lower IC50 in some chemotherapy-targeted drugs, that is, higher drug sensitivity.…”